These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 31786732)

  • 21. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
    Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
    Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ixekizumab for the treatment of psoriasis: up-to-date.
    Craig S; Warren RB
    Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
    Blauvelt A; Gooderham M; Iversen L; Ball S; Zhang L; Agada NO; Reich K
    J Am Acad Dermatol; 2017 Nov; 77(5):855-862. PubMed ID: 28917383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatol; 2024 May; 51(5):649-658. PubMed ID: 38482898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
    Leonardi C; Maari C; Philipp S; Goldblum O; Zhang L; Burkhardt N; Ball S; Mallbris L; Gonzalez P; Fernández-Peñas P; Puig L
    J Am Acad Dermatol; 2018 Nov; 79(5):824-830.e2. PubMed ID: 29803904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
    Paul C; Griffiths CEM; van de Kerkhof PCM; Puig L; Dutronc Y; Henneges C; Dossenbach M; Hollister K; Reich K
    J Am Acad Dermatol; 2019 Jan; 80(1):70-79.e3. PubMed ID: 29969700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis.
    Shelton SK; Bai SR; Jordan JK; Sheehan AH
    Ann Pharmacother; 2019 Mar; 53(3):276-284. PubMed ID: 30187769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study).
    Chiricozzi A; Megna M; Giunta A; Carrera CG; Dapavo P; Balato A; Malagoli P; Mazzoccoli S; Parodi A; Sabatino S; Buzzoni C; Huang CH; Narcisi A
    J Dermatolog Treat; 2023 Dec; 34(1):2246606. PubMed ID: 37587870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors.
    García-Martín E; Romero-Jiménez RM; Baniandrés-Rodríguez O; Escudero-Vilaplana V; Benedí-González J; de Los Ríos Luna PM; Herranz-Alonso A; Sanjurjo-Sáez M
    Eur J Hosp Pharm; 2024 Aug; 31(5):409-415. PubMed ID: 37094886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
    Valenti M; Gargiulo L; Ibba L; Malagoli P; Amoruso F; Balato A; Bardazzi F; Burlando M; Carrera CG; Dapavo P; Dini V; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Maurelli M; Megna M; Orsini D; Travaglini M; Costanzo A; Narcisi A
    Dermatol Ther (Heidelb); 2024 Jun; 14(6):1649-1657. PubMed ID: 38748344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
    Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
    J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
    Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
    Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
    Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
    J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.
    Ohata C; Ohyama B; Katayama E; Nakama T
    J Dermatol; 2020 Apr; 47(4):405-408. PubMed ID: 31994229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis.
    Tham LS; Tang CC; Choi SL; Satterwhite JH; Cameron GS; Banerjee S
    J Clin Pharmacol; 2014 Oct; 54(10):1117-24. PubMed ID: 24752880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies.
    Schwartzman S; Puig L; Cohen AD; Khattri S; Jossart C; Diaz C; Garrelts A; Ngantcha M; Eberhart N; Eleftheriadi A; Tangsirisap N; Schuster C; Gottlieb AB
    Expert Opin Drug Saf; 2024 Oct; 23(10):1347-1357. PubMed ID: 39234767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events.
    Gulliver W; Penney M; Power R; Gulliver S; Montmayeur S; Burge R
    J Dermatolog Treat; 2022 Feb; 33(1):354-360. PubMed ID: 32319327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.